✨BeCareLink was proud to present at the American Academy of Neurology on the potential of the #BeCareMSApp to assess relative #functional #improvement in patients based on the type of MS therapy used. 📱👏
While disease progression in MS remains a challenge—especially in cases of Progression Independent of Relapse Activity (PIRA)—our findings suggest that digital tools can offer new insight. In a comparison of over 380 app users, those on high efficacy therapies (e.g., anti-CD20 monoclonal antibodies, S1P modulators) showed greater improvements in cognitive, memory, and motor functions than those on low efficacy treatments.
The BeCare MS App shows promise as a digital tool for monitoring MS disability and PIRA progression, giving clinicians and patients a continuous, objective view of subtle changes.